What is TRexBio?
Founded in 2018, TRexBio operates at the intersection of advanced computational science and human immunology. The company specializes in the characterization of regulatory T cells (Tregs) within human tissue, utilizing a sophisticated discovery platform to decode disease-specific biological processes. This unique approach allows the firm to pinpoint therapeutic targets that were previously inaccessible, positioning it as a high-value player in the biopharmaceutical sector. By focusing on the fundamental mechanisms of immune regulation, TRexBio aims to deliver transformative treatments for patients suffering from chronic inflammatory conditions and cancer.
How much funding has TRexBio raised?
TRexBio has raised a total of $303M across 4 funding rounds:
Series A
$85M
Not Disclosed
$84M
Series B
$84M
Other Financing Round
$50M
Series A (2022): $85M with participation from Lilly, SV Health Investors, Johnson & Johnson Innovation, Pfizer Ventures, and Alexandria Venture Investments
Not Disclosed (2024): $84M led by Agent Capital and Delos Wealth Advisors
Series B (2024): $84M supported by Agent Capital, Polaris Partners, Eli Lilly and Company Pvt, Avego, Alexandria Venture Investments LLC Alexandria Venture Investments, Johnson & Johnson MedTech, SV Health Investors, Pfizer, and Delos Capital
Other Financing Round (2026): $50M featuring Delos Capital, Johnson & Johnson Innovation, Janus Henderson Investors, Polaris Partners, Avego, Affinity Asset Advisors, Lilly, SV Health Investors, and Balyasny Asset Management
Key Investors in TRexBio
Lilly
Eli Lilly and Company is a global biopharmaceutical firm engaged in the discovery, development, manufacturing, and commercialization of prescription medicines, with a strong focus on immunology and oncology.
SV Health Investors
SV Health Investors is a specialist investment firm backing innovative health care and life science companies, providing capital and sector expertise from early growth through scale.
Johnson & Johnson Innovation
Johnson & Johnson Innovation partners with entrepreneurs and early-stage businesses to develop healthcare solutions that improve lives globally through a network of regional innovation centers.
What's next for TRexBio?
With the successful closure of this latest capital round, TRexBio is well-positioned to scale its discovery engine and advance its lead candidates toward clinical validation. The strategic focus will likely shift toward expanding its internal research capabilities and strengthening its collaborative network with global pharmaceutical partners. As the company matures, the emphasis will remain on translating deep biological insights into scalable, high-impact therapeutic interventions, ensuring that its pipeline remains robust against the backdrop of a competitive and rapidly innovating biotechnology market.
See full TRexBio company page
